Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4303335 | 0.99 | KCNH2 (0.98) | KCNH2 | |
| SCHEMBL21198615 | 0.91 | KCNH2 (0.83) | KCNH2 | |
| SCHEMBL3865277 | 0.89 | KCNH2 (0.81) | KCNH2 | |
| SCHEMBL2797844 | 0.89 | KCNH2 (0.81) | KCNH2 | |
| Hydrochloric Acid SCHEMBL4131088 | 0.89 | KCNH2 (0.80) | KCNH2 | |
| Hydrochloric Acid SCHEMBL2796943 | 0.89 | KCNH2 (0.80) | KCNH2 | |
| Hydrochloric Acid SCHEMBL4299484 | 0.89 | KCNH2 (0.80) | KCNH2 | |
| SCHEMBL3839424 | 0.88 | KCNH2 (0.78) | KCNH2 | |
| SCHEMBL703873 | 0.88 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL3359359 | 0.88 | KCNH2 (0.84) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | claimed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | claimed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | claimed |
| EP-1893599-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | claimed |
| WO-2006134378-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | claimed |
| US-20210052597-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | CADILA HEALTHCARE LIMITED (IN) | 2021-02-25 | — | — | US | disclosed |
| WO-2019145919-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | CADILA HEALTHCARE LIMITED (IN) | 2019-08-01 | — | — | WO | disclosed |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| EP-1893599-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2006134378-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | KCNH2 2142/4885 |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885 |
| US-20210052597-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | ABCB11, DHPS, MRPL21 | KCNH2 1415/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.